Page details
First discovered on:
11:25pm, 11/08/10

All tags for this page:
0%
0 folks

OFIRMEV’s Europe Track Record, A Good Omen for US Market, Cad

www.tapebeat.com/2010100611829/Companies-Profile... - Details

TapeBeat: OFIRMEV’s Europe Track Record, A Good Omen for US Market, Cadence Pharmaceuticals (CADX) LINK ... Cadence Pharmaceuticals Inc’s (NASDAQ: CADX) drug OFIRMEV™ is currently under review at FDA with a new Prescription Drug User Fee Act(PDUFA)...

Save this page to your bookmarks.

Tagged and described by the following users:

TapeBeat saved this page on 10/05/2010 08:04pm

OFIRMEV’s Europe Track Record, A Good Omen for US Market, Cadence Pharmaceuticals (CADX) LINK ... Cadence Pharmaceuticals Inc’s (NASDAQ: CADX) drug OFIRMEV™ is currently under review at FDA with a new Prescription Drug User Fee Act(PDUFA) action date or FDA approval decision date of November 4

This URL was also folkd by:

by